Gliomas are the most common type of primary brain tumors that start in the brain or spinal cord. Gliomas are composed predominantly of astrocytomas, oligodendrogliomas, ependymomas, and mixtures of various glial cells such as oligoastrocytomas or glioblastoma with an oligodendroglial component. On average, 5 out of every 100,000 people suffer from malignant glioma per year. Although malignant glioma is relatively uncommon, it has an extremely high recurrence and mortality rates. People with malignant gliomas may have the following symptoms: headaches, nausea and vomiting, epilepsy, focal neurologic deficits, memory loss, confusion, cognitive dysfunction, personality changes and other symptoms.
Somatic mutations in the IDH1 gene encoding cytosolic NADP+-dependent isocitrate dehydrogenase, occur after the formation of low-grade glioma and promote tumor progression to glioblastoma. IDH1 gene variants regularly appear in astrocytomas, oligodendrogliomas and oligoastrocytomas. The pathological variations in the IDH2 gene which encoding mitochondrial NADP+-dependent isocitrate dehydrogenase are also discovered in these tumors, however, with lower frequencies. Mutations in TP53, PTEN, CDKN2A and EGFR often occur in different processes of tumor development. For example, in the development of astrocytoma, the TP53 mutation is often detected at an early stage, while the PTEN mutation and EGFR amplification are detected in higher-grade tumors. PTEN is a tumor suppressor gene that negatively regulates the PI3K pathway and mutations in EGFR often cause defects in growth factor signaling pathways. Mutations and genetic rearrangements of BRAF are associated with pilocytic astrocytomas and pleomorphic xanthoastrocytomas.
To support clinical researches, CD Genomics offers a predesigned glioma gene panel sequencing for genes which are frequently mutated and associated with gliomas. Targeted DNA sequencing technology that enables deep sequencing at high coverage levels is provided. Our glioma panel can be applied to efficiently discover, validate and screen genetic variants among the glioma genes and help researchers decode the complexities of glioma biology quickly. In addition, you can choose the panel content from our predesigned library or discuss your custom glioma requirements, then we can provide you with your own panel.
We provide customized bioinformatics analysis including:
CD Genomics provides the accurate and cost-effective glioma gene panel sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for glioma gene panel sequencing is outlined below.
For more information about the glioma gene panel or need other amplification requirements, please contact us.